Respiratory safety pharmacology - current practice and future directions.
Current practice in respiratory safety pharmacology generally follows the guidance provided by the ICH document S7A and, in general, focuses on measures of pulmonary ventilation. Respiratory rate, tidal volume and/or a measure of arterial blood gases are the recommended ventilatory measurement parameters. Although these parameters will provide a measure of ventilation, other ventilatory parameters, which can provide mechanistic insight, should also be considered. Such parameters include inspiratory and expiratory times and flows and apneic time. Stimulation models involving exercise and exposure to elevated CO2 or reduced O2 should also be considered when enhancing measurement sensitivity or quantifying reductions in ventilatory functional reserve are desired. Although ventilatory measurements are capable of assessing the functional status of the respiratory pumping apparatus, such measurements are generally not capable of assessing the status of the other functional component of the respiratory system, namely, the gas exchange unit or lung. To characterize drug-induced effects on the gas exchange unit, measures of airway patency, lung elastic recoil and gas diffusion capacity need to be considered. Thus, a variety of methodologies and measurement endpoints are available for detecting and characterizing drug-induced respiratory dysfunction in animal models and should be considered when designing respiratory safety pharmacology studies.
['Murphy|Dennis J|DJ|']
D000818:Animals D064420:Drug-Related Side Effects and Adverse Reactions D006801:Humans D012119:Respiration D012137:Respiratory System D012140:Respiratory Tract Diseases
Respiratory Safety pharmacology ICHS7A Methods Nonclinical PharmaPendium™ Regulatory